US Patent Issued to D3 Bio (Wuxi) on Jan. 13 for "Thiazololactam compound as ERK inhibitor and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Jan. 13 -- United States Patent no. 12,522,616, issued on Jan. 13, was assigned to D3 Bio (Wuxi) Co. Ltd. (Wuxi, China).

"Thiazololactam compound as ERK inhibitor and use thereof" was invented by Yi Li (Shanghai), Ning Liu (Shanghai), Tao Yu (Shanghai), Chengde Wu (Shanghai), Jian Li (Shanghai) and Shuhui Chen (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a thiazololactam compound, and the use thereof in the preparation of a drug for treating ERK-related diseases. Specially, the present invention provides a compound as shown in formula (III) or a pharmaceutically acceptable salt thereof."

The patent was filed on Dec. 7, 2020, under Application No. 17/782,814.

*For f...